A Phase I, Open Label, Multi Centre Study in Healthy Volunteers to Estimate the Effect of Multiple Doses of AZD2066 on the Activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 by Administering a Cocktail of Caffeine, Bupropion, Tolbutamide, Omeprazole, Metoprolol and Midazolam.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 2066; Bupropion; Caffeine; Metoprolol; Midazolam; Omeprazole; Tolbutamide
- Indications Diabetic neuropathies; Gastro-oesophageal reflux; Neuropathic pain
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 28 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2009 New trial record